We study how tumors begin, adapt, and resist treatment — turning fundamental discoveries into earlier detection and therapies that reach patients faster.
Helixa is a team of oncologists, molecular biologists, and data scientists working across four labs. We focus on the hardest questions in cancer biology — tumor heterogeneity, drug resistance, and early detection — and share everything we learn openly.
Using single-cell sequencing and live tumor imaging, we map how cancer cells evolve, communicate, and evade the immune system.
Patient-derived organoids let us trial hundreds of drug combinations against real tumor tissue — before a single patient is enrolled.
Promising findings move into clinical trials with our hospital partners, and every dataset is published openly for the wider field.
"The early-detection blood panel Helixa developed found my recurrence eight months before a scan would have. That head start changed everything."
"Their organoid screening platform compressed two years of our drug-resistance research into six months. Few labs share methods this openly."
"Every grant dollar comes with a report showing exactly where it went — samples sequenced, trials opened, papers published. Rare transparency."
Every contribution funds sequencing runs, trial enrollments, and the young scientists asking tomorrow's questions. 92¢ of every dollar goes directly to research.
Donate to the institute